Vasonatrin Peptide VNP |
رقم الكتالوجGC34228
One-Click Copy Product Info
|
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 141676-35-9
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Vasonatrin peptide (VNP) is a chimera of atrial natriuretic peptide (ANP) and C-type natriuretic peptide (CNP) with potent venodilating and natriuretic activity.
Vasonatrin peptide binds with both natriuretic peptide receptor A and B, but with a preference for B. VNP-stimulated cGMP is 11-fold greater in NPRB than NPRA[1].
The high-fat diet-fed streptozotocin-induced diabetic Sprague-Dawley rats are subjected to ischemia-reperfusion operation. VNP treatment (100 g/kg iv, 10 min before reperfusion) significantly improved the instantaneous first derivation of left ventricle pressure (LV dP/dtmax) and LV systolic pressure and reduced LV end-diastolic pressure, apoptosis index, caspase-3 activity, plasma creatine kinase (CK), and lactate dehydrogenase (LDH) activities[2]. Treatment hypoxia-induced pulmonary hypertension (HPH) with Vasonatrin peptide for 1 week significantly reduceS mean pulmonary arterial pressure, pulmonary vascular resistance, RVH and muscularization of the pulmonary arteries. Acute intravenous administration of 50 microg/kg Vasonatrin peptide significantly ameliorates pulmonary haemodynamics in HPH rats[3].
[1]. Jiang YS, et al. Vasonatrin peptide stimulates both of the natriuretic peptide receptors, NPRA and NPRB. Biochem Biophys Res Commun. 2014 Apr 18;446(4):1276-80. [2]. Shi Z, et al. Vasonatrin peptide attenuates myocardial ischemia-reperfusion injury in diabetic rats and underlying mechanisms. Am J Physiol Heart Circ Physiol. 2015 Feb 15;308(4):H281-90. [3]. Yu J, et al. Protective effects of vasonatrin peptide against hypobaric hypoxia-induced pulmonary hypertension in rats. Clin Exp Pharmacol Physiol. 2010 Jan;37(1):69-74.
Animal experiment: | Rats[2]The hypoxia-induced pulmonary hypertension (HPH) model is developed by subjecting rats to hypobaric hypoxia. The HPH rats are then treated with either VNP (50 lg/kg per day, i.p.) or saline (0.5 mL, i.p.) every day for 7 days. Haemodynamic indices, right ventricular hypertrophy (RVH) and remodelling of the pulmonary arteries are evaluated. In addition, plasma levels of atrial natriuretic peptide (ANP), endothelin (ET)-1 and angiotensin II (AngII) are determined, as is natriuretic peptide receptor-C (NPR-C) mRNA expression in the right ventricle[2]. |
References: [1]. Jiang YS, et al. Vasonatrin peptide stimulates both of the natriuretic peptide receptors, NPRA and NPRB. Biochem Biophys Res Commun. 2014 Apr 18;446(4):1276-80. | |
| Cas No. | 141676-35-9 | SDF | |
| Canonical SMILES | Gly-Leu-Ser-Lys-Gly-Cys-Phe-Gly-Leu-Lys-Leu-Asp-Arg-Ile-Gly-Ser-Met-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr (Disulfide bridge: Cys6-Cys22) | ||
| Formula | C123H198N36O36S3 | M.Wt | 2865.37 |
| الذوبان | Soluble in Water | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 349 μL | 1.745 mL | 3.49 mL |
| 5 mM | 69.8 μL | 349 μL | 698 μL |
| 10 mM | 34.9 μL | 174.5 μL | 349 μL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)